



*****URGENT NOTICE*****

Generic to NAPRELAN® 500mg Tablets Unavailable

- **August 13, 2008** – Watson Pharmaceuticals, Inc. announced that the United States District Court for the Southern District of Florida ruled that Watson’s Naproxen Sodium ER Tablets, the generic of NAPRELAN® 500mg Tablets infringes Elan’s U.S. patent No. 5,637,320.
- **August 22, 2008** – Watson Pharmaceuticals, Inc. announced that Naproxen Sodium ER 500mg Tablets are unavailable until further notice and all backorders will be canceled.
- **October 6, 2008** – NAPRELAN® 500mg Tablets are now listed as a Single Source Brand with no generic equivalents by the data service providers.

✓ **NAPRELAN® is the only once-daily naproxen / naproxen sodium product in the U.S. market with the patented IPDAS delivery system.**

✓ **NAPRELAN® has no generic equivalents; Rx Only.**

Product	NDC	Bottle Size	WAC
NAPRELAN® 500	68453-850-75 or 68453-0850-75	75 tablets	\$227.66

Place Your Order Today!

Cardiovascular Risk

- NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (See WARNINGS).
- Naproxen as NAPRELAN® is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (See WARNINGS).

Gastrointestinal Risk

- NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (See WARNINGS).

Please see enclosed NAPRELAN® full prescribing information including BOXED warnings regarding cardiovascular and gastrointestinal risks.

NAPRELAN® is a Registered Trademark of Elan Corporation plc
 IPDAS® is a Registered Trademark of Elan Pharma International Ltd.